Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ATP4A | P20648 | 2/20 | 0.34 |
| ▸ | ATP4B | P51164 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.30 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.30 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6529295 | 1.00 | ELANE (0.35) | ELANEATP4AATP4BKIF11HCRTR1 | |
| SCHEMBL7107773 | 1.00 | ELANE (0.35) | ELANEATP4AATP4BKIF11HCRTR1 | |
| SCHEMBL5746631 | 0.84 | ELANE (0.34) | ELANEATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL4972816 | 0.83 | ELANE (0.32) | ELANE | |
| SCHEMBL4972810 | 0.83 | ELANE (0.32) | ELANE | |
| SCHEMBL5745520 | 0.83 | ELANE (0.36) | ELANEHCRTR1TP53MAPTALOX15 | |
| SCHEMBL5041462 | 0.83 | ELANE (0.38) | ELANEATP4AATP4BKIF11CYP3A4 | |
| SCHEMBL5044812 | 0.80 | KIF11 (0.38) | ATP4AATP4BKIF11CYP3A4CYP2C9 | |
| SCHEMBL6672735 | 0.77 | ELANE (0.37) | ELANEATP4AATP4BCYP3A4CYP2C9 | |
| SCHEMBL5744048 | 0.77 | ELANE (0.37) | ELANEATP4AATP4BCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314935-B2 | Tricyclic n-acyl compounds | ALTANA PHARMA AG (DE) | 2008-01-01 | — | — | US | disclosed |
| EP-1414821-B1 | TRICYCLIC EPOXIDES | ALTANA PHARMA AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-6927292-B2 | Tricyclic epoxides | ALTANA PHARMA AG (DE) | 2005-08-09 | — | — | US | disclosed |
| US-20050148618-A1 | Tricyclic n-acyl compounds | ALTANA PHARMA AG (DE) | 2005-07-07 | — | — | US | disclosed |
| US-20040235882-A1 | Amino-substituted imidazopyridines for the treatment of gastrointestial diseases | ALTANA PHARMA AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040235883-A1 | Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders | ALTANA PHARMA AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040176597-A1 | Tricyclic epoxides | ALTANA PHARMA AG (DE) | 2004-09-09 | — | — | US | disclosed |
| EP-1419156-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA Pharma AG (DE) | 2004-05-19 | — | — | EP | disclosed |
| EP-1417208-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA Pharma AG (DE) | 2004-05-12 | — | — | EP | disclosed |
| EP-1414821-A1 | TRICYCLIC EPOXIDES | ALTANA Pharma AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003016310-A1 | ALKYL-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | ALTANA PHARMA AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003014120-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDINES FOR THE TREATMENT OF GASTROINTESTINAL DISEASES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-2003014119-A1 | TRICYCLIC EPOXIDES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235883-A1 | Alkyl-substituted imidazopyridines for the treatment of gastrointestinal disorders | SLC10A2, ALPI, SI | ELANE 1466/4885ATP4A 235/4885ATP4B 701/4885 |
| US-20040235882-A1 | Amino-substituted imidazopyridines for the treatment of gastrointestial diseases | SLC10A2, ALPI, FABP6 | ELANE 754/4885ATP4A 314/4885ATP4B 626/4885 |
| US-20050148618-A1 | Tricyclic n-acyl compounds | NAT1, AADAC, CYP1B1 | ELANE 671/4885ATP4A 2068/4885ATP4B 1914/4885 |
| US-20040176597-A1 | Tricyclic epoxides | VKORC1, CYP2E1, CYP1A2 | ELANE 327/4885ATP4A 1792/4885ATP4B 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.